



Vivimed

Date: 30/05/2019

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Sub.: Outcome of the Board Meeting held on May 30, 2019

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that:

1. The Board of Directors (the Board") at its meeting held today i.e. May 30, 2019 has considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2019. Please find enclosed said Audited Results along with Audit Report and Form A.
2. The meeting of the Board of Directors of the Company commenced at 3:00 P.M and concluded at 11.00 P.M .

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Vivimed Labs Ltd

Santosh Varalwar
Managing Director



VIVIMED LABS LIMITED
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2019

All amounts in Rs. Lakhs

Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
	Income From Operations					
1	Revenue from operations	34,807.56	24,392.89	28,560.95	1,31,517.03	1,18,566.03
	Total revenue from operations	34,807.56	24,392.89	28,560.95	1,31,517.03	1,18,566.03
2	Other Income	610.18	631.31	287.23	2,296.00	960.96
3	Total Revenue (1+2)	35,417.75	25,024.20	28,848.18	1,33,813.03	1,19,526.99
4	Expenses					
a	Cost of material consumed	16,088.15	9,827.40	13,204.27	56,191.14	48,980.29
b	Purchases of Stock- in- Trade				-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(2,407.47)	(894.22)	(2,339.01)	(4,351.28)	(1,012.92)
d	Employee Benefit Expenses	7567.85	4,226.92	5,830.35	24,176.00	19,777.71
e	Finance Costs	1283.21	1,755.75	1,636.63	6,726.22	7,948.30
f	Depreciation and Amortisation Expenses	1605.26	1,529.04	1,383.95	6,678.97	5,641.96
g	Other Expenses	11420.62	7,558.35	8,490.94	37,787.43	29,620.58
	Total Expenses	35,557.61	24,003.24	28,207.13	1,27,208.49	1,10,955.92
5	Profit before tax (3-4)	(139.87)	1,020.96	641.05	6,604.54	8,571.07
6	Tax expenses					
	Current Taxes	(132.40)	(41.31)	(18.73)	780.20	1,217.93
	Deferred Taxes	(8.82)	(21.93)	(231.27)	87.70	(255.81)
	Total tax expenses	(141.22)	(63.24)	(250.00)	867.90	962.12
7	Profit for the period /Year before non-controlling interest (5-6)	1.36	1,084.21	891.05	5,736.64	7,608.96
8	Non-controlling interest			185.29		185.29
9	Profit for the period/ year (7-8)	1.36	1,084.21	1,076.34	5,736.64	7,794.25
10	Other comprehensive income					
	Items that will not be reclassified to profit or loss, net of tax	-		(36.61)		(65.68)
	Items that will be reclassified to profit or loss, net of tax					
	Total other comprehensive income	-	-	(36.61)	-	(65.68)
11	Non-controlling interest	-	-	-	-	185.29
12	Other comprehensive income attributable to shareholders(10+11)	-	-	(36.61)	-	119.61
	Total comprehensive income attributable to:					
	Shareholders of the Company	-		1,039.73		7,728.57
	Non-controlling interest	1.36	1,084.21	(185.29)	5,736.64	-
	Total Comprehensive income	1.36	1,084.21	854.44	5,736.64	7,543.28
18	Paid up Equity Share Capital	1,650.48	1,650.48	1,650.48	1,650.48	1,650.48
19	Other equity					88,467.24
20	Earnings per Share (before Extraordinary Items) (of Rs2/- each)	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	(a) Basic	0.00	1.31	1.08	6.95	9.22
	(b) Diluted	0.00	1.26	1.07	6.67	9.11

1. The above Consolidated Audited Financial Results for the Quarter & Year ended March 31.03.2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30.05.2019

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma Pvt Limited (ii) Vivimed Speciality chemicals Pvt Ltd and its wholly owned foreign subsidiaries viz(i) Vivimed Labs USA, Inc.,(ii)Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its Step-down subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimico Farmaceutica S.A.U., Spain, (viii) Holliday International Limited,UK & (ix) Uquifa Mexico S.A. de C.V.(x) Vivimed Labs (Mascarene) Ltd (xi) Soneas Chemicals Ltd (xii) Soneas Research Ltd and its wholly owned Indian subsidiary (i) UQUIFA India Private Limited and its Indian subsidiary (i) Vivimed Life Sciences Pvt Ltd.(sold on 29th January 2019).

3. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date: 30.05.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS

All amounts in Rs. lakhs

Particulars	3 Months Ended			Year Ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	3415.807	4,204.28	4,286.85	16,269.77	20,034.63
b.Pharma Business	31391.75	20,188.61	24,274.10	1,15,247.27	98,531.39
Total	34,807.56	24,392.89	28,560.95	1,31,517.03	1,18,566.02
Less, Inter Segment Revenue	-	-	-	-	-
Net sales / Income from Operations	34,807.56	24,392.89	28,560.95	1,31,517.03	1,18,566.02
2. Segment Results Profit / (Loss) before tax and interest from each segment					
a.Speciality Chemicals Business	447.83	851.04	764.12	4,363.34	6,223.17
b.Pharma Business	656.06	1,925.67	1,513.57	8,967.48	10,296.17
Total	1,103.89	2,776.71	2,277.69	13,330.83	16,519.34
Less: 1.Interest	1267.65	1,755.75	1,636.63	6,726.22	7,948.27
2.Other Un-allocable Expenditure					
3.Un-allocable Income					
Total Profit Before Tax	(163.76)	1,020.96	641.06	6,604.60	8,571.07
3. Capital Employed					
a.Speciality Chemicals Business	1,17,181.04	See Note	96,411.16	1,17,181.04	96,411.16
b.Pharma Business	79,745.06	See Note	1,02,444.56	79,745.06	1,02,444.56
	1,96,926.10		1,98,855.72	1,96,926.10	1,98,855.72
a.Segment Assets	2,32,916.69	See Note	2,39,362.76	2,32,916.69	2,39,362.76
b.Segment Liabilities	1,38,537.26	See Note	1,15,494.89	1,38,537.26	1,15,494.89

Note:

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad

Date : 30.05.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2019

All amounts in Rs. Lakhs

Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
	Income From Operations					
1	Revenue from operations	7459.95	5,171.80	6,799.06	25,180.77	26,138.59
	Total revenue from operations	7,459.95	5,171.80	6,799.06	25,180.77	26,138.59
2	Other Income	764.14	16.81	145.38	853.42	192.95
3	Total Revenue (1+2)	8,224.09	5,188.61	6,944.43	26,034.19	26,331.54
4	Expenses					
a	Cost of material consumed	3807.81	2,006.37	3,198.05	12,770.31	11,494.73
b	Purchases of Stock- in- Trade					-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(1,477.39)	(449.23)	(1,207.40)	(4,740.37)	(2,854.63)
d	Employee Benefit Expenses	1263.96	832.55	911.55	3,787.52	3,408.63
e	Finance Costs	1813.68	1,131.27	1,385.55	5,240.31	5,180.22
f	Depreciation and Amortisation Expenses	469.92	430.87	400.08	1,825.90	1,814.36
g	Other Expenses	2136.96	1,207.25	2,031.05	6,637.50	6,403.01
	Total Expenses	8,014.94	5,159.08	6,718.89	25,521.16	25,446.33
5	Profit before tax (3-4)	209.15	29.53	225.55	513.03	885.20
6	Tax expenses					
	Current Taxes	-42.36	1.52	44.03	103.79	170.25
	Deferred Taxes	-	(78.49)	(271.76)	(209.31)	(271.76)
	Total tax expenses	(42.36)	(76.97)	(227.73)	(105.52)	(101.51)
7	Profit for the period /Year before non-controlling interest (5-6)	251.51	106.50	453.28	618.55	986.71
8	Non-controlling interest					
9	Profit for the period/ year (7-8)	251.51	106.50	453.28	618.55	986.71
10	Other comprehensive income					
	Items that will not be reclassified to profit or loss, net of tax			(36.29)		
	Items that will be reclassified to profit or loss, net of tax					(65.37)
	Total other comprehensive income	-	-	(36.29)	-	(65.37)
11	Non-controlling interest	-	-	-	-	-
12	Other comprehensive income attributable to shareholders(10+11)	-	-	-	-	(65.37)
	Total comprehensive income attributable to:					
	Shareholders of the Company	251.51	106.50	416.99	618.55	921.35
	Non-controlling interest	-	-	-	-	-
	Total Comprehensive income	251.51	106.50	416.98	618.55	921.35
18	Paid up Equity Share Capital	1,650.48	1,650.48	1,650.48	1,650.48	1,650.48
19	Other equity					55,090.47
20	Earnings per Share (before Extraordinary items) (of Rs2/- each) (not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	(a) Basic	0.30	0.13	0.55	0.75	1.20
	(b) Diluted	0.29	0.12	0.54	0.72	1.18

1. The above Standalone Audited Financial Results for the Quarter & Year ended March 31, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30.05.2019. The Financial results are prepared in accordance with the Indian Accounting standards(IndAS) as prescribed under section 133 of the Companies Act,2013 read with the Companies (Indian Accounting Standards)Rules,2015 (as amended).

2. In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.

3. Corresponding numbers of previous period / year have been regrouped, wherever necessary.



For VIVIMED LABS LIMITED

(SANTOSH YABALKWAR)
MANAGING DIRECTOR

Place : Hyderabad
Date: 30.05.2019

VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED

All amounts in Rs. Lakhs


Particulars	3 Months Ended			Year Ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	659.89	1,129.31	2,077.62	5,651.77	7,161.20
b.Pharma Business	6,316.84	4,042.50	4,721.44	19,045.78	18,977.38
Total	6,976.73	5,171.80	6,799.06	24,697.55	26,138.59
Less, Inter Segment Revenue					
Net sales / Income from Operations	6,976.73	5,171.80	6,799.06	24,697.55	26,138.59
2.Segment Results Profit / (Loss) before tax and interest from each segment					
a.Speciality Chemicals Business	210.77	201.26	719.80	888.47	2,037.46
b.Pharma Business	1812.06	959.54	891.30	4,864.87	4,027.96
Total	2,022.83	1,160.80	1,611.10	5,753.34	6,065.42
Less: 1.Interest	1,813.68	1,131.27	1,385.55	5,240.31	5,180.22
2.Other Un-allocable Expenditure					
3. Un-allocable Income					
Total Profit Before Tax	209.15	29.53	225.55	513.03	885.20
3. Capital Employed					
a.Speciality Chemicals Business	69,248.66	See Note	71,873.81	69,248.66	71,873.81
b.Pharma Business	41,107.24	See Note	39,566.02	41,107.24	39,566.02
	1,10,355.90		1,11,439.83	1,10,355.90	1,11,439.83
4.					
a.Segment Assets	1,15,455.79	See Note	1,25,541.39	1,15,455.79	1,25,541.39
b. Segment Liabilities	58,193.79	See Note	68,800.44	58,193.79	68,800.44

Note:

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it was impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad
Date : 30.05.2019



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
Balance Sheet

All amounts in Rs. Lakhs

Particulars	Standalone		Consolidated	
	As at 31 March 2019	As at 31 March 2018	As at 31 March 2019	As at 31 March 2018
ASSETS				
Non current assets				
Property, Plant and Equipment	33,563.69	35,664.35	66,203.28	74,471.60
Intangible assets	4,506.70	4,818.65	30,288.90	29,064.00
Capital work in progress	6,418.04	4,277.64	12,230.73	6,527.14
Financial assets				
Investments	8,753.04	15,186.57	251.00	269.92
Deferred tax assets, net	-	-	679.17	785.73
Other non-current assets	-	-	202.65	50.31
Total non current assets	53,241.47	59,947.21	1,09,855.74	1,11,168.70
Current assets				
Inventories	28,244.66	29,253.99	56,368.61	54,016.56
Financial assets				
Trade receivables	10,188.57	16,767.12	35,611.03	27,542.97
Cash and cash equivalents	2,495.83	917.85	9,530.38	9,903.30
Loans	6,842.27	5,821.07	7,568.83	8,471.40
Others	-	-	10.79	7.81
Current tax assets, net	1,990.93	254.84	1,990.93	3,241.70
Other current assets	12,452.06	12,579.31	11,980.37	25,010.32
Total current assets	62,214.32	65,594.18	1,23,060.95	1,28,194.06
Total assets	1,15,455.79	1,25,541.39	2,32,916.69	2,39,362.76
EQUITY AND LIABILITIES				
Equity				
Equity share capital	1,650.48	1,650.48	1,650.48	1,650.48
Instruments entirely equity in nature	-	-	32,522.05	32,522.05
Other equity	55,611.52	55,090.47	60,206.90	88,467.23
Total equity	57,262.00	56,740.95	94,379.43	1,22,639.76
Non-controlling interests	-	-	-	1,228.11
Non current liabilities				
Financial Liabilities				
Borrowings	8,971.04	11,595.66	42,480.11	32,519.63
Others	12,449.51	13,528.50	3,085.50	2,335.96
Deferred tax liabilities, net	987.23	1,333.54	-	-
Other Non current liabilities	979.90	1,653.89	3,157.11	913.40
Provisions	953.77	716.90	921.11	702.74
Total non current liabilities	24,341.45	28,828.49	49,643.83	36,471.73
Current liabilities				
Financial Liabilities				
Borrowings	21,412.59	25,870.39	33,230.09	38,516.12
Trade payables	3,528.56	2,338.64	29,442.40	20,199.37
Other financial liabilities	5,323.40	7,599.61	21,933.83	13,981.62
Other current liabilities	77.68	77.61	776.97	782.84
Provisions	-	55.24	-	55.24
Current tax liabilities	3,510.11	4,030.46	3,510.13	5,487.97
Total liabilities	33,852.34	39,971.95	88,893.43	79,023.16
Total equity and liabilities	1,15,455.79	1,25,541.39	2,32,916.69	2,39,362.76





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com


Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of Vivimed Labs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

**To Board of Directors of
Vivimed Labs Limited**

1. We have audited the accompanying Statement of Consolidated Financial Results of M/s **Vivimed Labs Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred as "the Group") for the quarter and for the period from 1st April 2018 to 31st March, 2019 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ("the circular"). The quarterly consolidated financial results are the derived figures between the audited figures in respect of the year ended 31st March, 2019 and the published year-to-date figures up to December 31, 2018, being the date of the end of the third quarter of the current financial year, which are subject to limited review. This Statement, which is the responsibility of the Holdings Company's management, has been prepared on the basis of the related consolidated financial statements which is in accordance with the Accounting Standards, prescribed under Section 133 of the Companies Act, 2013, as applicable, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Holding Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

3. We did not audit the financial statements of all the 16 subsidiaries whose financial statements/consolidated financial statements reflect total assets before elimination of Rs. 2788.40 crores as at 31.03.2019 and the total revenue of Rs.1138.32 crores for the year then ended which are considered in preparation of the Statement. These interim financial statements and other financial information have been prepared by the management whose reports have been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim unaudited financial statements is based solely on the report of Management.
4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly consolidated financial results as well as the consolidated year to date financial results :
- (i) Include the quarterly and year to date financial results of the following entities:
- (a) Finoso Pharma Pvt Limited
 - (b) Vivimed Speciality chemicals Pvt Ltd
 - (c) Vivimed Labs USA, Inc.,
 - (d) Vivimed Labs Mauritius Limited
 - (e) Vivimed Holdings Limited
 - (f) Vivimed Labs Europe Limited
 - (g) Vivimed Labs UK Limited
 - (h) Vivimed Labs Spain, S.L.
 - (i) Union Quimico Farmaceutica S.A.U., Spain
 - (j) Holliday International Limited,UK
 - (k) Uquifa Mexico S.A. de C.V.
 - (l) Vivimed Labs (Mascarene) Ltd
 - (m) Soneas Chemicals Ltd
 - (n) Soneas Research Ltd
 - (o) UQUIFA India Private Limited
 - (p) Vivimed Life Sciences Pvt Ltd (Sold on 29th January 2019)
- (ii) is prepared in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ; and
- (iii) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and other financial information of the Company for the year ended 31st March 2019.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

For P C N & Associates .,
Chartered Accountants
(Firm's RegnNo.016016S)

Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 30th May 2019



P C N & ASSOCIATES

CHARTERED ACCOUNTANTS

Plot No. 12, "N Heights"

Ground Floor, Software Layout Unit

Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of M/s. Vivimed Labs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

To Board of Directors of
Vivimed Labs Limited

1. We have audited the quarterly financial results of M/s. **Vivimed Labs Limited** for the quarter ended March 31, 2019 and to the year to date financial results for the year ended March 31, 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016('the circular'), except for the disclosures regarding Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2019 and the published year-to-date figures up to December 31, 2018, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2019 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2018, the audited annual financial statements as at and for the year ended March 31, 2019, and the relevant requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2018 which was prepared in accordance with applicable Ind AS and other recognised accounting policies laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies(Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2019; and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

2. These financial results have been prepared on the basis of Ind AS financial statements and reviewed quarterly financial results up to the end of the third quarter, which are the responsibility of Companies Management. Our responsibility is to express an opinion on these financial results based on our Audit of such annual Ind AS Financial statements, which has been prepared in accordance with the recognised and measurements principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act, 2013 and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 , as amended in this regard; and
 - (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2019 as well as the year to date results for the period from April 1, 2018 to March 31, 2019.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

For P C N & Associates .,
Chartered Accountants
(Firm's RegnNo.016016S)

Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 30th May 2019



Vivimed

Date: 30/05/2019

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Sub: Declaration – reg.

Ref: Regulation 33 of the SEBI (LODR) (Amendment) Regulations, 2016

Pursuant to the requirement as specified under Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI ((Listing Obligations and Disclosure Requirements) (amendment) Regulations 2016, it is hereby declared that the Auditors Report for the financial year ended as on March 31, 2019 contains unmodified opinion as provided under the independent Auditors Report which is attached herewith for your reference.

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Vivimed Labs Ltd

Santosh Varalwar
Managing Director




FORM A


(For audit report on consolidated financial results with unmodified opinion)

1	Name of the Company	VIVIMED LABS LIMITED
2	Annual financial statements for the year ended	31 st March, 2019
3	Type of Audit observation	Un-modified
4	Frequency of observation	Not Applicable

For Vivimed Labs Limited



Santosh Varalwar
Managing Director
(DIN: 00054763)




Umanath Varahabhotla
Chairman of Audit Committee
(DIN: 06539204)



For P C N & Associates,
Chartered Accountants
(Firm's RegnNo.016016S)


Chandra Babu M
Partner
M.No. 227849




FORM A


(For audit report on Standalone financial results with unmodified opinion)

1	Name of the Company	VIVIMED LABS LIMITED
2	Annual financial statements for the year ended	31 st March, 2019
3	Type of Audit observation	Un-modified
4	Frequency of observation	Not Applicable

For Vivimed Labs Limited



Santosh Varalwar
Managing Director
(DIN: 00054763)




Umanath Varahabhotla
Chairman of Audit Committee
(DIN: 06539204)



For P C N & Associates,
Chartered Accountants
(Firm's RegnNo.016016S)


Chandra Babu M
Partner
M.No. 227849

